Outlook Therapeutics, Inc.
Patent Applications and Registrations
Patent applications and USPTO patent grants for Outlook Therapeutics, Inc..The latest application filed is for "buffered formulations of bevacizumab for use of treating diseases".
- Outlook Therapeutics, Inc. - Cranbury NJ US
Trademarks
| Patent | Date |
|---|---|
| Buffer formulations for enhanced antibody stability Grant 11,285,210 - Gutka , et al. March 29, 2 | 2022-03-29 |
| Buffered Formulations Of Bevacizumab For Use Of Treating Diseases App 20210230261 - YONAN; Chris ; et al. | 2021-07-29 |
| Modulation of charge variants in a monoclonal antibody composition Grant 10,696,735 - Yonan , et al. June 30, 2 | 2020-06-30 |
| Buffer formulations for enhanced antibody stability Grant 10,376,582 - Cini , et al. A | 2019-08-13 |
| Modulation Of Afucosylated Species In A Monoclonal Antibody Composition App 20190161543 - SANTORO; Marc ; et al. | 2019-05-30 |
| SEC | 0001649989 | Outlook Therapeutics, Inc. of DELAWARE |
| SEC | 1649989 | Outlook Therapeutics, Inc. of DELAWARE |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 